Saneca Pharmaceuticals, a.s. has acquired Suir Pharma Ireland
Saneca Pharmaceuticals, a.s. (Saneca) has acquired Suir Pharma Ireland from mutares AG, an industrial holding company. Financial details have not been disclosed.
Saneca is a pharmaceutical contract manufacturing company active in the development, production, registration and distribution of generic medicines and active pharmaceutical ingredients. Saneca also owns a portfolio of cosmetic and generic products.
Suir Pharma Ireland is an independent contract manufacturing company working with many established pharmaceutical companies worldwide. Formerly a Stada AG manufacturing site, Suir Pharma Ireland is well known as an established manufacturer of generic medicines for more than 40 years with the highest quality standards. The company supplies various markets in Europe and the USA.
mutares AG is an industrial holding company that focuses on the acquisition of companies currently finding themselves in a special situation, such as owner or management succession, strategic repositioning and re-funding.
Oaklins' team in Slovakia advised the buyer in this transaction.
Talk to the deal team
Related deals
Top Systems teams up with Holland Capital to create the premier Dutch battery-based solutions provider
Holland Capital, a Netherlands-based private equity firm, has acquired a stake in Top Systems, a leading provider of complete battery-based power solutions, with a unique value-added services proposition.
Learn moreInfotreasury has been sold to Matera
Matera, a leading banking software company with world-class instant payments and core banking solutions, has acquired Infotreasury.
Learn moreThrive Freeze Dry has successfully sealed the acquisition deal with Paradiesfrucht GmbH
Paradiesfrucht GmbH, a gobal freeze dryer of fruits, fruit preparations, drops, powders and granulates, has been acquired by Thrive Freeze Dry (Thrive), a portfolio company of Entrepreneurial Equity Partners (e2p) and Mubadala Capital. The transaction is expected to close in 2024, subject to customary closing conditions, including antitrust approval.
Learn more